Luo Jing-Ru, Xiang Xiao-Jun, Xiong Jian-Ping
Int J Clin Pharmacol Ther. 2016 Sep;54(9):719-22. doi: 10.5414/CP202577.
Imatinib mesylate, the first agent approved for the treatment of unresectable or metastatic gastrointestinal stromal tumor, is a tyrosine kinase inhibitor targeting (KIT) and the platelet-derived growth factor receptor-α and -β. However, imatinib administration can be accompanied by various adverse events. Here we report a case of Lichenoid drug eruption (LDE) that appeared 24 weeks after commencement of imatinib in a 73-year-old man with gastrointestinal stromal tumor (GIST). The skin lesions were distributed over his face, trunk and limbs, which improved only after discontinuation of imatinib therapy. To the best of our knowledge, this is the first report of imatinib-induced LDE in the Chinese population.
甲磺酸伊马替尼是首个被批准用于治疗不可切除或转移性胃肠道间质瘤的药物，它是一种靶向KIT以及血小板衍生生长因子受体α和β的酪氨酸激酶抑制剂。然而，服用甲磺酸伊马替尼可能会伴随各种不良事件。在此，我们报告一例73岁胃肠道间质瘤（GIST）男性患者，在开始服用甲磺酸伊马替尼24周后出现苔藓样药疹（LDE）。皮肤损害分布于面部、躯干和四肢，仅在停用甲磺酸伊马替尼治疗后有所改善。据我们所知，这是中国人群中关于甲磺酸伊马替尼诱发LDE的首例报告。
